Premium
Formula Supplemented with Docosahexaenoic Acid (DHA) and Arachidonic Acid (ARA): A Critical Review of the Research
Author(s) -
Wright Kristen,
Coverston Catherine,
Tiedeman Mary,
Abegglen Jo Ann
Publication year - 2006
Publication title -
journal for specialists in pediatric nursing
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.499
H-Index - 38
eISSN - 1744-6155
pISSN - 1539-0136
DOI - 10.1111/j.1744-6155.2006.00048.x
Subject(s) - docosahexaenoic acid , arachidonic acid , randomized controlled trial , medicine , cognition , fatty acid , chemistry , biochemistry , polyunsaturated fatty acid , psychiatry , enzyme
PURPOSE. To summarize results of randomized controlled trials (RCTs) evaluating growth, cognitive, neurological, and visual development of term infants supplemented with docosahexaenoic acid (DHA) and arachidonic acid (ARA).DESIGN AND METHODS. The Boyack and Lookinland Methodological Quality Index (MQI) was used to evaluate data from RCTs identified from multiple data bases.RESULTS. Six of ten studies found the addition of DHA and ARA to have no significant effect on infant development.PRACTICE IMPLICATIONS. More expensive formula with endogenous DHA and ARA is not necessary. Results from longer studies currently underway will be beneficial.